Related Experiment Video
Updated: Jun 3, 2025
07:03
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
770
Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid
Ye Sun1, Qingling Chen1, Yuxiao Liu2
1Department of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing.
The Journal of Infectious Diseases
|January 8, 2025
Summary
Hepatitis B virus infection disrupts fatty acid metabolism and mitochondrial function. Decanoylcarnitine supplementation improves these conditions by activating CPT1A and the PPAR signaling pathway, offering therapeutic potential.
Area of Science:
- Hepatology
- Mitochondrial Biology
- Metabolic Disorders
Background:
- Increasing incidence of metabolic-associated steatotic liver disease in hepatitis B patients.
- Unclear interaction between hepatitis B virus (HBV) infection and lipid metabolism.
- Need to understand if regulating fatty acid metabolism can mitigate HBV-induced mitochondrial dysfunction.
Purpose of the Study:
- To investigate the impact of HBV infection on fatty acid metabolism and mitochondrial function.
- To determine if decanoylcarnitine can alleviate HBV-induced mitochondrial dysfunction.
- To elucidate the underlying molecular pathways involved.
Main Methods:
- Analysis of human liver gene sets and proteomic analysis of mouse livers.
- In vivo and in vitro investigation of decanoylcarnitine's effect on fatty acid β-oxidation and mitochondria.
- Confirmation of involved pathways using Western blot.
Main Results:
- HBV infection leads to fatty acid β-oxidation disorder and mitochondrial dysfunction.
- CPT1A overexpression and decanoylcarnitine supplementation improved mitochondrial function and fatty acid metabolism.
- Decanoylcarnitine activated CPT1A expression and stimulated the PPAR signaling pathway, particularly PPARα.
Conclusions:
- Exogenous decanoylcarnitine partially restored impaired fatty acid metabolism and mitochondrial function in HBV-infected hepatocytes.
- Decanoylcarnitine shows therapeutic potential for HBV infection.
- This study offers a new therapeutic approach for diseases involving mitochondrial dysfunction.
Related Concept Videos
01:17Hepatic Drug Excretion: Enterohepatic Cycling
979
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
979
01:28Overview of Fatty Acid Metabolism
30.2K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
30.2K